These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9598535)

  • 1. Penile fracture after intracavernous injection therapy.
    Fazeli-Matin S; Montague DK; Angermeier KW; Lakin MM
    J Urol; 1998 Jun; 159(6):2094. PubMed ID: 9598535
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous injection of papaverine, phentolamine and phenoxybenzamine.
    Pettirossi O; Serenelli G
    Acta Urol Belg; 1988; 56(2):211-9. PubMed ID: 3400527
    [No Abstract]   [Full Text] [Related]  

  • 7. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
    Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
    Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
    Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
    Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
    Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
    J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endocavernous drug infusions revisited].
    Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.
    Tarhan F; Canguven O; Kuyumcuoglu U
    J Sex Med; 2006 Mar; 3(2):377. PubMed ID: 16490038
    [No Abstract]   [Full Text] [Related]  

  • 15. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernous injections for impotence.
    Med Lett Drugs Ther; 1990 Dec; 32(834):116-7. PubMed ID: 2255296
    [No Abstract]   [Full Text] [Related]  

  • 17. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.
    Shamloul R; Atteya A; Elnashaar A; Gadallah A; Zohdy W; Abdelsalam W
    J Sex Med; 2005 Jan; 2(1):117-20. PubMed ID: 16422914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacotherapy of erectile dysfunction].
    Shcheplev PA; Nesterov SN; Kukharkin SA; Abdullaev IA; Sidorov DV
    Ter Arkh; 1999; 71(10):76-8. PubMed ID: 10612182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.